These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 25911892)
1. Clinical characteristics and prognostic factors of gastroenteropancreatic neuroendocrine tumors: a single center experience in China. Hu HK; Ke NW; Li A; Du XJ; Guo Q; Hu WM Hepatogastroenterology; 2015; 62(137):178-83. PubMed ID: 25911892 [TBL] [Abstract][Full Text] [Related]
2. Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria. Ozkara S; Aker F; Yesil A; Senates E; Canbey C; Yitik A; Gonen C Hepatogastroenterology; 2013 Oct; 60(127):1665-72. PubMed ID: 24627925 [TBL] [Abstract][Full Text] [Related]
3. The importance of clinical information in patients with gastroenteropancreatic neuroendocrine tumor. Kudo A; Akashi T; Kumagai J; Ban D; Inokuchi M; Kojima K; Kawano T; Tanaka S; Arii S Hepatogastroenterology; 2012; 59(120):2450-3. PubMed ID: 22584507 [TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China. Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502 [TBL] [Abstract][Full Text] [Related]
6. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296 [TBL] [Abstract][Full Text] [Related]
7. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection. Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559 [TBL] [Abstract][Full Text] [Related]
8. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival. Keck KJ; Choi A; Maxwell JE; Li G; O'Dorisio TM; Breheny P; Bellizzi AM; Howe JR Ann Surg Oncol; 2017 Aug; 24(8):2206-2212. PubMed ID: 28560597 [TBL] [Abstract][Full Text] [Related]
9. Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms. Pommergaard HC; Nielsen K; Sorbye H; Federspiel B; Tabaksblat EM; Vestermark LW; Janson ET; Hansen CP; Ladekarl M; Garresori H; Hjortland GO; Sundlöv A; Galleberg R; Knigge P; Kjaer A; Langer SW; Knigge U J Neuroendocrinol; 2021 May; 33(5):e12967. PubMed ID: 33769624 [TBL] [Abstract][Full Text] [Related]
10. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study. Shi H; Zhang Q; Han C; Zhen D; Lin R BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596 [TBL] [Abstract][Full Text] [Related]
11. Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors. Watanabe A; Yip L; Hamilton TD; Loree JM; Stuart HC Am J Surg; 2021 Jun; 221(6):1141-1149. PubMed ID: 33795127 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading. Sugimoto M; Takagi T; Hikichi T; Suzuki R; Watanabe K; Nakamura J; Kikuchi H; Konno N; Waragai Y; Asama H; Takasumi M; Watanabe H; Obara K; Ohira H World J Gastroenterol; 2015 Jul; 21(26):8118-24. PubMed ID: 26185384 [TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study. Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205 [TBL] [Abstract][Full Text] [Related]
14. [Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms]. Li Y; Wang YF; Tan BB; Er LM; Zhao Q; Fan LQ; Zhang ZD; Liu Y Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):426-431. PubMed ID: 32482035 [No Abstract] [Full Text] [Related]
15. Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years. Baptiste GG; Postlewait LM; Ethun CG; Le N; McInnis MR; Russell MC; Winer JH; Kooby DA; Staley CA; Maithel SK; Cardona K J Surg Oncol; 2016 Aug; 114(2):163-9. PubMed ID: 27157897 [TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine tumors: analysis from a single-institution. Zeng YJ; Liu L; Wu H; Lai W; Cao JZ; Xu HY; Wang J; Chu ZH Asian Pac J Cancer Prev; 2013; 14(10):5775-81. PubMed ID: 24289577 [TBL] [Abstract][Full Text] [Related]
17. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival. Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic and therapeutic role of endoscopy in gastroenteropancreatic neuroendocrine neoplasms. Attili F; Capurso G; Vanella G; Fuccio L; Delle Fave G; Costamagna G; Larghi A Dig Liver Dis; 2014 Jan; 46(1):9-17. PubMed ID: 23731843 [TBL] [Abstract][Full Text] [Related]
19. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892 [TBL] [Abstract][Full Text] [Related]
20. Larger Tumor Size and Elevated Serum Chromogranin A Levels Predict Metastatic Disease on DOTATATE Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors. Labora A; Shimizu T; Moore A; Premji A; Armstrong WR; Chen KY; Link J; Chan CS; Allen-Auerbach MS; Donahue TR Ann Surg Oncol; 2024 Oct; 31(10):6875-6882. PubMed ID: 38909116 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]